NEW YORK, July 18 – Ventana Medical Systems said Wednesday that GlaxoSmithKline has chosen its Discovery in situ hybridization and immunohistochemistry system for use in DNA and protein expression experiments.
GlaxoSmithKline will install six to eight of Ventana’s systems in its European and North American research facilities, Ventana CEO Christopher Gleeson told GenomeWeb. The two companies will also collaborate to develop improvements in tissue gene expression profiling methods.
Ventana’s Discovery system automates the wet chemistry steps required for analyzing gene and protein expression experiments using DNA microarrays and tissue samples. The systems can analyze about 20 glass slides at a time using a carousel-type mechanism, and typically cost about $150,000, Gleeson said. Additional modules for added throughput cost about $120,000.
Ventana has installed about 40 of the systems in US pharmaceutical and biotechnology company research labs since the company introduced the system in November 2000, Gleeson said.
Last week, Tucson, Ariz.-based Ventana signed an agreement with BD Biosciences Clontech Laboratories in which the companies will non-exclusively co-market each other’s microarray products.